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Multiple myeloma (MM) is a malignant neoplasm of plasma
cells. Although new molecular targeting agents against MM
have been developed based on the better understanding of the
underlying pathogenesis, MM still remains an incurable
disease. We previously demonstrated that b-catenin, a down-
stream effector in the Wnt pathway, is a potential target in MM
using RNA interference in an in vivo experimental mouse
model. In this study, we have screened a library of more than
100000 small-molecule chemical compounds for novel Wnt/
b-catenin signaling inhibitors using a high-throughput trans-
criptional screening technology. We identiﬁed AV-65, which
diminished b-catenin protein levels and T-cell factor transcrip-
tional activity. AV-65 then decreased c-myc, cyclin D1 and
survivin expression, resulting in the inhibition of MM cell
proliferation through the apoptotic pathway. AV-65 treatment
prolonged the survival of MM-bearing mice. These ﬁndings
indicate that this compound represents a novel and attractive
therapeutic agent against MM. This study also illustrates
the potential of high-throughput transcriptional screening to
identify candidates for anticancer drug discovery.
Blood Cancer Journal (2011) 1, e43; doi:10.1038/bcj.2011.41;
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Introduction
Multiple myeloma (MM) is a malignant neoplasm of plasma
cells characterized by frequent chromosomal translocations and
gene mutations.
1 High-dose chemotherapeutics in conjunction
with hematopoietic stem cell transplantation has been one
standard clinical course of the treatment of MM.
2–4 As we gain a
better understanding of the pathogenesis underlying MM, new
molecular targeting agents can be developed.
5,6 Nevertheless,
MM remains incurable at present.
7 Thus, it is important to
continue to investigate new therapeutic agents that focus on
targeting the biology of MM cells.
b-Catenin is a downstream effector in the canonical
Wnt signaling pathway; thus, it is involved in the regulation
of cell fate, proliferation and the self-renewal of stem cells.
In the absence of Wnt ligands, cytosolic b-catenin undergoes
proteasomal degradation through sequential phosphorylation
and ubiquitination.
8,9 In the process, b-catenin that is phos-
phorylated by casein kinase I, and subsequently glycogen
synthase kinase-3b, forms a degradation complex comprised
of glycogen synthase kinase-3b, casein kinase I, axin and
adenomatous polyposis coli. Phosphorylated b-catenin is
ubiquitinated by cellular b-transducin repeat-containing
proteins (b-TrCP), and subsequently degraded by the 26S
proteasome.
10 Upon Wnt ligand binding to Frizzled receptors
and the co-receptor low-density lipoprotein receptor-related
protein 5 (LRP5) or LRP6, the dishevelled phosphoprotein
inactivates glycogen synthase kinase-3b, and the b-catenin
degradation complex dissociates, resulting in the stabilization of
b-catenin. Stabilized b-catenin translocates to the nucleus,
where it binds to lymphoid enhancer-binding factor (LEF) and
T-cell factor (TCF) proteins to activate the transcription of target
genes such as c-myc and cyclin D1, which are involved in cell
proliferation and survival.
11,12 Activation of Wnt signaling is
closely linked to the process of carcinogenesis.
13 Human MM-
derived cell lines and primary MM cells overexpress b-catenin,
whereas in normal plasma cells, b-catenin expression is
undetectable.
14–16 The recent study demonstrated that genes
of soluble Wnt signal antagonists were methylated in MM cells,
resulting in repression of their transcripts, and consequently, the
increased expression of b-catenin.
17 Overexpression of
b-catenin promotes transcriptional activity of target genes
related to the proliferation of MM cells, whereas inhibition of
Wnt/b-catenin signaling suppresses MM growth.
15,16 These
results suggest that b-catenin might be an attractive therapeutic
target for MM.
Progress in molecular biology has enabled signiﬁcant
advances in drug discovery strategies. For example, RNA
interference is a technique that can be used to knockdown the
expression of speciﬁc genes in treated cells. An altered
transcriptional proﬁle can then be used as a biomarker for a
speciﬁc molecular targeting, and quantitative evaluation can be
applied to high-throughput technology.
18,19 Using high-
throughput transcriptional screening technology (Supplementary
Figure 1), we identiﬁed effective inhibitors of the Wnt/b-catenin
signaling from a library of more than 100000 chemical
compounds (Supplementary Figure 2). From this initial series,
we optimized a novel Wnt/b-catenin signal inhibitor, AV-65,
that signiﬁcantly suppressed the growth of MM cells and
prolonged survival in a mouse model of orthotopic MM. These
results demonstrate that AV-65 is a novel and attractive
therapeutic agent for the treatment of MM.
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Cell lines, reagents and animals
Human AMO-1, KMS-12-BM, RPMI8226, NCI-H929, U226 and
OPM-2 myeloma cell lines, and the IM-9 Epstein–Barr virus-
transformed cell line derived from an MM patient, were
purchased from the Deutsche Sammlung von Mikroorganismen
und Zellkulturen GmbH (Braunschweig, Germany). RPMI8226/
LR5 melphalan-resistant cells were kindly provided by
Dr William S Dalton (University of South Florida, Tampa, FL,
USA).
20 HCT-15 colorectal adenocarcinoma cells were pur-
chased from American Tissue Culture Collection (Manassas,
VA, USA). The 293T cells were purchased from the Deutsche
Sammlung von Mikroorganismen und Zellkulturen GmbH.
IM-9, RPMI8226, NCI-H929 and U266 cells were cultured in
RPMI1640 (Gibco, Tokyo, Japan) containing 10% heat-inacti-
vated fetal calf serum (FCS; Invitrogen, Tokyo, Japan), 2mM
L-glutamine (Gibco) and 1% penicillin–streptomycin (Gibco).
The AMO-1 and KMS-12-BM cell lines were cultured in
RPMI1640 containing 20% FCS, 2mML -glutamine and 1%
penicillin–streptomycin. The RPMI8226/LR5 cell line was
cultured in media containing 10% FCS, 2mML -glutamine, 1%
penicillin–streptomycin and 5mM melphalan (Sigma-Aldrich,
Tokyo, Japan). Hepatocytes were cultured using CS-C complete
medium kit (Cell Systems, Kirkland, WA, USA). HCT-15
cells were cultured in RPMI1640 containing 5% FCS, 2mM
L-glutamine and 1% penicillin–streptomycin. The 293T cells
were cultured in Dulbecco’s modiﬁed Eagle’s medium contain-
ing 10% heat-inactivated fetal calf serum, 2mML-glutamine and
1% penicillin–streptomycin. All cell lines were maintained at
371C in a fully humidiﬁed atmosphere of 5% CO2 in air.
Peripheral blood mononuclear cells from three healthy
volunteers were isolated by using Ficoll–Hypaque (GE Healthcare
Japan, Tokyo, Japan), and cultured with in Iscove’s modiﬁed
Dulbecco’s medium (Gibco) containing 20% FCS, 2mM
L-glutamine and 1% penicillin–streptomycin. Bone marrow
(BM) samples were obtained from MM patients who were
hospitalized in the Hospital of Kyoto Prefectural University of
Medicine. In accordance with the Declaration of Helsinki
recommendations, all procedures were approved by the
institutional review board at Kyoto Prefectural University of
Medicine, and written informed consent was obtained from
every participant. Ficoll–Hypaque density centrifugation was
used to separate mononuclear cells, followed by magnetic cell
sorting (Miltenyi, Gladbach, Germany) using an anti-CD138
antibody (Ab) (Miltenyi) to enrich BM-derived MM cells. Cells
were analyzed by FACS Canto II using the Diva software (BD
Bioscience, Tokyo, Japan). The purity of the enriched CD138-
positive cell populations was X95%. Isolated MM cells were
cultured in RPMI1640 containing 10% FCS, 2mML -glutamine
and 20ng/ml human interleukin-6 (R&D Systems, Minneapolis,
MN, USA).
Speciﬁc pathogen-free 6- to 8-week old female nonobese
diabetic-severe combined immune deﬁciency (NOD/SCID)
mice (Clea Japan, Tokyo, Japan) were used for the in vivo
experiments. Approval for these studies was obtained from the
Committee on Animal Research of the Kyoto University Faculty
of Medicine.
Growth inhibitory effects on myeloma cells
Cell proliferation was evaluated by the modiﬁed MTT (3-(4,
5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay
using Cell-Counting Kit-8 (Dojindo Laboratory, Kumamoto,
Japan), as described previously.
21,22 Cells were seeded in a
ﬂat-bottomed 96-well plate (BD Bioscience) at a density of
3 10
3 cells in 100ml of medium per well, and then incubated
with serial dilutions of AV-65 for 72h. The mean of four samples
at each concentration was evaluated. Half maximal inhibitory
concentration values were obtained using the nonlinear regres-
sion program CalcuSyn (Biosoft, Cambridge, UK).
Western blot analysis
Following treatment with AV-65, more than 1 10
6 cells were
collected by centrifugation, and then the cells were washed with
ice-cold phosphate-buffered saline ( ) twice. Ice-cold radio-
immunoprecipitation assay buffer (50mM Tris-HCl (pH 7.4),
0.25 M NaCl, 5mM EDTA, 20mM NaF, 1% NP-40) containing
fresh phenylmethylsulfonyl (1mM) and protease inhibitor (10mg/ml)
was added to the cells. The suspension was transferred into a
centrifuge tube and placed on ice for 15min (min) with
occasional vortexing to ensure complete lysis of the cells. The
cell suspension was cleared by centrifugation at 14000g for
30min at 41C. Nuclear and cytoplasmic protein fractions were
obtained using NE-PER Nuclear and Cytoplasmic Extraction
Reagents Kit (Pierce Biotechnology, Rockford, IL, USA),
according to the manufacturer’s instructions. The supernatants
(total cell lysate, nuclear and cytoplasmic protein fractions)
were either used immediately or stored at  801C. Protein
concentrations were determined using the DC Protein Assay
(Bio-Rad Laboratories, Osaka, Japan). Immunoblotting was
performed as described previously.
16,21 Samples (20mgo f
protein) were analyzed using the following primary Abs, as
indicated: anti-b-catenin (BD Pharmingen, San Jose, CA, USA),
-Bad (Stressgen, Victoria, BC, Canada), -Bid (a kind gift from
Dr David CS Huang, The Walter and Eliza Hall Institute of
Medical Research (WEHI), Parkville, VIC, Australia),
23 -Bim
(clone 3C5, produced by Dr LA O’Reilly (WEHI)), -Bcl-2 (Bcl-2-
100; Upstate, Lake Placid, NY, USA), -Bcl-xL (Stressgen), -Puma
(ProSci, Poway, CA, USA), -Noxa (Alexis Biochemicals, Lausen,
Switzerland), -Mcl-1 (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), -c-myc (Santa Cruz Biotechnology), -cyclin D1 (BD
Pharmingen), -Oct-1 (Santa Cruz Biotechnology,), survivin (Cell
Signaling Technology, Danvers, MA, USA) and -actin (Sigma-
Aldrich). Horseradish peroxidase-coupled immunoglobulin G
(Amersham Biosciences, Tokyo, Japan) was used as a secondary
Ab, and immunoreactive proteins were detected by enhanced
chemiluminescence or ECL-plus kits (Amersham Biosciences).
Ubiquitination of b-catenin
At 12h after AV-65 treatment, whole-cell lysates were obtained
as described above. Lysates were subjected to immunoprecipi-
tation using an anti-b-catenin monoclonal Ab (BD Pharmingen)
and Dynabeads Protein A (Invitrogen), according to the
manufacturer’s instructions. Ubiquitination of b-catenin was
detected with anti-mono- and anti-poly-ubiquitinyl conjugates
(Enzo Life Sciences International Inc., Plymouth Meeting,
PA, USA).
TCF/LEF dual luciferase reporter assay
The activity of TCF/LEF transcription in HCT-15 cells was
evaluated with the Wnt Cignal Reporter Assay (SABioscience,
Fredrick, MD, USA). HCT-15 colorectal cancer cell line
expresses high levels of b-catenin
24 and is easily transfectable
with plasmids. For each sample, 3 10
4 HCT-15 cells were
reverse-transfected with 100ng of a TCF/LEF ﬁreﬂy luciferase
reporter plasmid and a constitutively expressing CMV-driven
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(SABioscience, Fredrick, MD, USA), according to the manufac-
turer’s instructions. At 16h post-transfection, media were
changed to assay media (Opti-MEM containing 0.5% FBS and
1% non-essential amino acids) for 8h, followed by AV-65
treatment for 14h. Relative luciferase activity of cells was
detected using the Dual-Luciferase Reporter Assay System
(Promega, Madison, WI, USA) and a Wallac Victor 1420 Plate
Reader (Perkin-Elmer, Waltham, MA, USA). The relative
luciferase activities generated by each well were calculated by
determining the ratio of the luciferase (ﬁreﬂy/Renilla) values to
normalize the signal. Three independent transfections were
carried out in duplicate for each of the concentrations tested.
Induction of apoptosis and cell cycle analysis
Cell cycle analysis using propidium iodide (PI) was performed
as described previously.
22 Apoptosis induced by AV-65 was
determined using Annexin-V-FITC Apoptosis Detection Kit I (BD
Bioscience), according to the manufacturer’s instructions. Cells
were analyzed by FACS Canto II using the Diva software (BD
Bioscience). Caspase-3, -8 and -9 activities in the presence of
AV-65 were evaluated using a ﬂuorometric protease assay
kit (MBL, Aichi, Japan), according to the manufacturer’s
instructions.
Lentiviral transduction
We produced b-TrCP knockdown IM-9 cells using a lentivirus
vector expressing short hairpin RNA against b-TrCP. Plasmids
expressing short hairpin RNA against b-TrCP and green
ﬂuorescent protein were provided by Dr Kenzo Tokunaga
(International Medical Center of Japan, Tokyo, Japan). The
lentiviral packaging plasmid psPAX2 was provided by Addgene
(Addgene plasmid 12260, D Trono, Lausanne, Switzerland).
The pHIT/G plasmid
25 expressing the vesicular stomatitis virus-
G protein was kindly provided by M Malim (University of
Pennsylvania, Philadelphia, PA, USA). In all, 10mgo fb-TrCP
short hairpin RNA, 10mg of psPAX2 and 10mg of pHIT/G were
added to a mixture of BES (N,N-bis[2-hydroxy-ethyl]-2-ami-
noethanesulfonic acid)-buffered saline and calcium chloride.
After incubation for 20min, the solution was added dropwise to
a 10cm dish of 70% conﬂuent 293T cells. The cells were
incubated for 12h at 371C in a humidiﬁed incubator with an
atmosphere of 3% CO2. The medium was replaced with 10mM
forskolin-containing medium and incubated at 371C and 10%
CO2. After 48h, the supernatants were harvested. In total,
1.0 10
6 IM-9 cells were transduced with 3ml of the super-
natant and polybrene (Sigma-Aldrich). We isolated GFP-positive
cells by using a limiting dilution method.
Real-time polymerase chain reaction
RNA was puriﬁed with the QIAamp RNA Blood Mini Kit
(Qiagen, Tokyo, Japan) and subjected to reverse transcription.
Human b-TrCP gene expression levels were measured by a real-
time polymerase chain reaction. A real-time polymerase chain
reaction mixture contained 4ml of Taqman master mix (Roche
Diagnostics GmbH, Mannheim, Germany), cDNA, pairs of
primers and Taqman probe (Universal Probe Library; Roche
Diagnostics GmbH). The cDNA was ampliﬁed with a Light
Cycler 3.5 (Roche Diagnostics GmbH) using the following
parameters: 951C for 10min, followed by 45 cycles of 951C for
15 s and 601C for 60s. Glyceraldehyde-3-phosphate was used
as an internal to normalize the loading difference. The primers
for b-TrCP were as follows: forward primer, CCAGATAAATAA
CCATACACTGACCTC and reverse primer, CAGATACGTTAAA
TACCGCAACTTT. The primers for glyceraldehyde-3-phosphate
were as follows: forward primer, AGCCACATCGCTCAGACAC
and reverse primer, GCCCAATACGACCAAATCC.
50 nM
1.0 1.0
1.25
PBMC-3
AMO-1
IM-9
PBMC-2
PBMC-1
1.5
 
500 nM
R
e
l
a
t
i
v
e
 
c
e
l
l
 
g
r
o
w
t
h
 
0
0.5
R
e
l
a
t
i
v
e
 
c
e
l
l
 
g
r
o
w
t
h
0.25
0.5
0.75 KMS-12-BM
NCIH929
OPM-2
RPMI8226
U266
RPMI8226/LR5
AV-65 (nM)
50 100 150 01 2 2 4 48 6
Time (h)
0
200 250 300
0.75
1.0
0.25
0.5
R
e
l
a
t
i
v
e
 
c
e
l
l
 
g
r
o
w
t
h
0
AV-65 (nM)
0
1000 500 100
Patient 1
Patient 2
Figure 1 Inhibition of myeloma cell proliferation. (a) The dose-dependent effect of compounds on the proliferation of myeloma cell lines was
evaluated by the modiﬁed MTT assay. Cells were incubated with serial dilutions of compounds for 72h. Data represent the means±s.d. of three
independent experiments, and four replicate experiments. (b) Time-dependent inhibition of proliferation of IM-9 cells. Cells were incubated with
AV-65 for 6, 12, 24 and 48h. Data represent the means±s.d. of three independent experiments, and four replicate experiments. (c) Effect of
compounds on CD138-positive myeloma cells and CD138-positive normal plasma cells. CD138-positive myeloma cells and CD138-normal
plasma cells were puriﬁed from BM mononuclear cells obtained from myeloma patients and healthy volunteers, respectively. Data represent the
mean of four replicates for each concentration.
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The in vivo inhibitory effects of AV-65 on MM cells were
investigated using an orthotropic mouse model. After exposure
to 2Gy of irradiation, speciﬁc pathogen-free 7- to 8-week old
female NOD/SCID mice (Japan Clea, Osaka, Japan) were
inoculated intravenously with 5 10
6 IM-9 cells in 100mlo f
phosphate-buffered saline through the tail vein. IM-9 cells were
successfully engrafted into the BM of all mice and IM-9-bearing
mice died of MM approximately 32 days after inoculation. For
the in vivo analysis of AV-65, the compound was formulated as
a solid dispersion of 20%, the active drug ingredient with 80%
of polyvinylpyrrolidine as an excipient to improve solubility.
The in vivo formulation was administered intravenously through
the tail vein in four cycles of 4 days on/1 day off, starting on the
day following inoculation of IM-9 cells.
To investigate whether AV-65 treatment induced myelosup-
pression, we performed the colony-forming assay. After four
cycles of AV treatment, NOD/SCID mice were killed and BM
cells were obtained. Mononuclear cells were obtained by
density centrifugation, and a colony-forming assay was
performed using MethoCult GF M3434 (Stem Cell Technologies
Inc., Vancouver, BC, Canada), according to the manufacturer’s
instructions. The complete blood counts of the mice treated with
vehicle or AV-65 were measured using the MEK-6450 Celltac a
cell counter (Nihon Kohden, Tokyo, Japan).
Statistical analysis
The in vivo effects of AV-65 treatment were analyzed using the
log-rank test; the effects of AV-65 on colony-forming ability and
complete blood counts were analyzed using the Student’s t-test.
A P-value of 0.05 was considered statistically signiﬁcant.
Results
Inhibitory effects of AV-65 on myeloma cells in vitro
AV-65 inhibited growth of seven MM cell lines and the
melphalan-resistant RMPMI8226/LR5 cell line in a dose-
dependent manner (Figure 1a), with IC50 values after 72h
exposures in the range of 11.7–82.1nM. However, AV-65 had
lesser effects on normal peripheral blood mononuclear cells
compared with MM cell lines (Figure 1a). AV-65 also inhibited
the growth of IM-9 cells in a time-dependent manner
(Figure 1b). CD138-positive myeloma cells obtained from MM
patients were growth-inhibited by AV-65 in a dose-dependent
manner (Figure 2c). Compared with the cell lines, higher doses
of AV-65 were required for killing primary MM cells,
presumably because the primary cells are quiescent and less
sensitive to cytotoxic stimuli ex vivo.
Alteration of b-catenin expression and TCF
transcriptional activity by AV-65
We next investigated alterations in b-catenin expression in MM
cells. The levels of b-catenin in both the cytoplasmic and the
nuclear fractions were diminished after 18h by AV-65 treatment
(Figure 2a). We also examined the ubiquitination of b-catenin in
IM-9 cells following 12h of exposure to AV-65. b-Catenin
complexes were captured by immunoprecipitation with an
anti-b-catenin Ab, and then analyzed by western blot using an
Ab speciﬁc for ubiquitin–protein conjugates. Higher molecular
weight ubiquitinated proteins were more prominent immuno-
precipitates from AV-65-treated cells (Figure 2b), which
suggested that AV-65 induces the degradation of b-catenin
through the ubiquitin–proteasome pathway.
We next investigated the modulation of TCF transcriptional
activity in AV-65-terated HCT-15 colorectal adenocarcinoma
cells using a TCF/LEF dual luciferase reporter assay. The cells
were transfected with a TCF/LEF ﬁreﬂy luciferase reporter
plasmid along with a constitutively active CMV-driven Renilla
luciferase reporter plasmid to ensure transfection efﬁciency.
Transcriptional activity in HCT-15 cells was decreased by
AV-65 treatment in a dose-dependent manner (Figure 3a).
Moreover, the expression of cyclin D1, c-myc and survivin,
which are downstream targets of TCF,
11,12,26–28 were sup-
pressed in IM-9 and U266 cells (Figure 3b). Taken together,
these results suggest that AV-65 enhances the ubiquitination and
subsequent proteasomal degradation of b-catenin, and that
b-catenin/TCF target gene promoter activity is decreased.
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Figure 2 Alteration of b-catenin expression in myeloma cells by
AV-65 treatment. (a) Cells were incubated with serial dilutions of AV-65
and harvested after 6, 12 and 18h. Nuclear and cytoplasmic protein
fractions were obtained and analyzed by western blot using an anti-b-
catenin Ab. Results are representative of three independent experi-
ments. (b) Ubiquitination of b-catenin by AV-65 treatment. Cells were
incubated with the indicated concentration of AV-65 (1 IC50), and
then harvested after 12h. Whole lysate was subjected to immunopre-
cipitation using an anti-b-catenin Ab, and immune complexes were
captured using protein A beads. The protein A slurry (30ml) was
analyzed by immunoblot using anti-mono- and anti-poly-ubiquitinyl
conjugates to detect ubiquitination of b-catenin (left panel). The bands
of about 60 and 30kDa detected in the membrane using anti-b-catenin
Ab are nonspeciﬁc (right panel).
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mediated ubiquitination
We have clariﬁed the mechanism by which AV-65 affects
b-catenin degradation. b-Catenin is a target for the ubiquitin–
proteasome pathway with b-TrCP, an ubiquitin ligase, triggering
the ubiquitination of b-catenin. We examined the interaction
between b-TrCP and b-catenin. The immunoprecipitation-
western blotting analysis revealed that AV-65 enhanced the
interaction of b-TrCP and b-catenin (Figure 4a).
We next established, using a lentivirus vector, a stable IM-9
cells containing a constitutive RNA interference capable of
knockdown of b-TrCP (b-TrCP-KD IM-9) (Figure 4b). In contrast
to IM-9 cells, the decrease of b-catenin was suppressed in
b-TrCP-KD IM-9 cells after exposure to AV-65 (Figure 4c). In
b-TrCP-KD IM-9 cells, AV-65-induced ubiquitination of
b-catenin was suppressed (Supplementary Figure 3). These
observations suggested that AV-65 degrades b-catenin through
enhancing b-TrCP-mediated ubiquitination.
Induction of apoptosis by AV-65
Upon cell cycle analysis, we detected an increase in the sub-G1
phase fraction by AV-65 treatment in a dose- and a time-
dependent manner (Supplementary Figures 4a and b, respec-
tively). We also examined the induction of apoptosis in
AV-65-treated cells by Annexin-V/propidium iodide staining.
Early apoptotic cells (Annexin-V-positive/propidium iodide -
negative), late apoptotic cells and necrotic cells (Annexin-
V-positive/propidium iodide -positive) increased in a dose- and
time-dependent manner (Figure 5a and Supplementary Figure 5,
respectively). These results indicated that AV-65 inhibits the
proliferation of MM cells through the induction of apoptosis.
We next investigated the underlying mechanism of apoptosis
induced by AV-65 using a ﬂuorometric protease assay. AV-65
treatment activated caspase-3, caspase-8 and caspase-9, in-
dicating that apoptosis by AV-65 involves the activation of both
intrinsic and extrinsic apoptotic pathways (Figure 5b). Western
blot analysis showed that the expression of Noxa was increased
in IM-9, AMO-1 and OPM-2 cells by AV-65 treatment, and the
expression of Bad and BimS was increased in U266 cells. In
AMO-1 cells, tBid and Noxa levels were increased, and the
expression of Noxa was increased in OPM-2 cells. No
signiﬁcant changes in the expression of antiapoptotic proteins
such as Bcl-2, BCl-xL and the long isoform of Mcl-1 were
observed (Supplementary Figure 6). These ﬁndings suggested
that AV-65 induces apoptosis accompanied with the activation
of caspases through the cell type-dependent activation of
proapoptotic BH-3-only proteins.
Inhibitory effects on myeloma in vivo
We assessed the in vivo effects of AV-65 on the growth of
MM cells in vivo in an orthotopic mouse model of MM.
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Figure 3 Inhibition of b-catenin-TCF signaling by AV-65 treatment.
(a) Inhibition of TCF transcriptional activity in HCT-15 colorectal
cancer cells. Cells were co-transfected with a TCF/LEF ﬁreﬂy luciferase
reporter, and a CMV-driven Renilla luciferase reporter. To normalize
transfection efﬁciency, cells were incubated with AV-65 for 14h, and
then luciferase activity was measured. Data represent the mean±s.d.
of three independent experiments. The relative TCF transcription
activity represents the difference between the relative luciferase units
of treated versus non-treated cells. (b) Decreased expression of TCF
downstream targets in IM-9 cells. Cells were incubated with serial
dilutions of AV-65 and then harvested at 24h. Harvested cells were
lysed in radioimmunoprecipitation assay buffer. Cell extracts (20mgo f
protein) was analyzed by western blot using the indicated Abs. Cyclin
D1 and c-myc were not expressed in IM-9 and U266 cells,
respectively.
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detect binding between b-catenin and b-TrCP. (b) IM-9 cells were
transduced with lentivirus-based short hairpin RNAs targeting b-TrCP
and control vector. b-TrCP levels were measured by real-time
polymerase chain reaction. Data represent the means±s.d. of three
independent experiments, and four replicate experiments. (c) The
alterations of b-catenin expression in IM-9 cells (left panel) and
b-TrCP-KD IM-9 cells (right panel) by AV-65 treatment. After 24h
incubation with serial dilutions of AV-65, cells were harvested, and
were lysed in radioimmunoprecipitation assay buffer. Cell extracts
(20mg of protein) were analyzed by western blot using an anti-b-
catenin Ab and an anti-b-TrCP Ab.
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animals died of MM by approximately 32 days after transplanta-
tion (Figure 6a and Supplementary Figure 7). When we
administered AV-65 to MM-bearing mice intravenously, the
survival of mice treated with the higher doses of AV-65 was
signiﬁcantly prolonged as compared to vehicle-treated mice
(P¼0.028; Figure 6a). To investigate the adverse effects of
AV-65 in treated mice, we assayed colony-forming activity in
BM and other biochemical parameters in AV-65 and vehicle-
treated mice. There were no statistical differences in body
weight (data not shown), the complete blood cell counts
between the groups (Figure 6b) or the numbers of colony-
forming units in BM (Figure 6c). These observations indicated
that AV-65 is a potent therapeutic agent for MM and does not
induce severe adverse effects.
Discussion
Over the past 20 years, drug discovery has been dominated by
phenotypic screening based on cancer cell biology. Using a
traditional, pharmacology-driven approach, compounds that
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Figure 5 Induction of apoptosis in myeloma cells by AV-65. (a) Cells were incubated with serial dilutions of AV-65 and harvested after 24h. Data
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identiﬁed. Advances in molecular biology and genetic engineer-
ing has brought out the era of chemical genetics,
29 leading to
well-characterized selective cancer-speciﬁc drugs such as
imatinib and trastuzumab, which target speciﬁc molecular
pathways. In recent years, the Human Genome Project and
related efforts have led to the establishment of databases based
on genomics and transcriptome analyses, and transcriptional
proﬁling and high-throughput technology using microarrays
have been applied to systemic drug screening.
30 Proﬁling the
expression of numerous gene sets in normal versus pathological
states can provide critical clues to intracellular signaling
pathway function, as well as to identities of genes that play
important roles in carcinogenesis.
b-Catenin is a downstream effector of the canonical Wnt
signaling pathway. The activation of Wnt signaling is closely
linked to carcinogenesis,
13,31,32 and b-catenin is considered a
valid drug target known to regulate the Wnt pathway.
27,33 In
support of this, downregulation of b-catenin by small interfering
RNA inhibits the proliferation of cancer cells.
16,34,35 Recently, a
study describing the high-throughput transcriptional screening
analysis (Supplementary Figure 1) of HT29 colon adenocarci-
noma cells transfected with an small interfering RNA against
b-catenin was reported.
18 In HT-29 cells, b-catenin over-
expression correlates with carcinogenesis due to mutation of
adenomatous polyposis coli,
11 making these cells a useful
model system. Transcriptional changes before and after knock-
down of b-catenin were proﬁled using a gene expression
microarray, and nine genes (CTNNB1, NM_001904; CEA-
CAM6, NM_002483; EMP1, NM_001423; IHH, NM_002181;
MYEF2, NM_016132; NTN4, NM_021229; DHRS9,
NM_005771; HMGB1, NM_002128; and GAPDH,
NM_002046; GAPDH was used as control) were identiﬁed as
candidate genes that were modulated by inhibition of the Wnt/
b-catenin pathway. The gene set was then validated using a
series of small-molecule probes that are known inhibitors of the
Wnt/b-catenin signaling (that is, indomethacin and retinoic
acid).
36–38 A random forest algorithm developed during the
signature validation phase was used to identify hit compounds
from the screening library. Hit compounds and closely related
analogs were re-tested in escalating doses to conﬁrm activity
and measure potency, and several early-stage compound series
was selected for further analysis as inhibitors of the Wnt/b-
catenin pathway. Ultimately, the LC-363 compound series
(Supplementary Figure 2) were selected for further analysis as an
inhibitor of the Wnt/b-catenin pathway. AV-65 was generated
based on initial LC-363 series. Our preliminary data show that
this AV-65 compound was more potent in inhibiting the Wnt/b-
catenin signaling than the early-stage compound series (data not
shown). Lepourcelet et al.
39 screened several antagonistic
compounds for their ability to inhibit the b-catenin pathway
using a high-throughput method for immunoenzymatic detec-
tion based on protein–protein interactions. The screened
compounds were from natural sources, and several of them
shared polyhydroxylated planar features. One of these com-
pounds, PKF115-584, inhibited the proliferation of MM cells.
15
SDX-308, an etodolac analog, also induced cytotoxicity in MM
cells through inhibition of the b-catenin pathway.
40 By
comparison, this novel compound of this study is fundamentally
different from these earlier compounds in both structure and
function.
We ﬁrst examined the in vitro effects of AV-65 on MM cells.
AV-65 inhibited the proliferation of MM cells in a dose- and a
time-dependent manner (Figures 1a and b, respectively). More-
over, b-catenin was degraded in AV-65-treated cells through an
increase in ubiquitination (Figure 2b). The results of a dual
luciferase reporter assay indicated that AV-65 inhibits TCF
transcriptional activity, and that c-myc, cyclin D1 and survivin
expression is decreased by AV-65 (Figures 3a and b). Moreover,
b-catenin was degraded in AV-65-treated cells through an
increase in ubiquitination (Figure 2b). Moreover, AV-65
enhanced the interaction between b-catenin and b-TrCP,
resulting in the increased ubiquitination and degradation of
b-catenin. The involvement of b-TrCP was veriﬁed by experi-
ments showing knockdown of b-TrCP (Figure 4). AV-65
inhibited TCF/LEF transcriptional activity, resulting in a decrease
in the level of TCF downstream targets and the induction of
apoptosis through the activation of caspases (Figures 5a and b).
Thus, AV-65 inhibits the Wnt/b-catenin signaling through the
decrease of b-catenin/TCF transcriptional activity, resulting in
the suppression of MM cell proliferation.
We also investigated the in vivo effects of a water-soluble
formulation of AV-65. Survival of MM-bearing mice was
signiﬁcantly prolonged by administration of AV-65 (Figure 6a).
AV-65 had no adverse effects on the mice, in terms of body
weight (data not shown), the number of the peripheral blood
cells or the colony-forming units in the BM (Figures 6b and c).
We are planning to carry out a phase I study with this compound
series in solid and hematopoietic malignancies.
In conclusion, a novel Wnt/b-catenin signaling inhibitor,
AV-65, inhibited the proliferation of MM cells in vivo and in vitro.
Thus, b-catenin represents a promising molecular target for therapy
against MM, and AV-65 a promising agent against MM.
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Figure 6 The in vivo inhibitory effects of AV-65 on MM cells in an
orthotopic mouse model. Following irradiation (2Gy), speciﬁc
pathogen-free 7- to 8-week old female NOD/SCID mice were
inoculated intravenously with 5 10
6 IM-9 cells in 100ml phos-
phate-buffered saline through the tail vein. The day after inoculation,
AV-65 was administered intravenously for four cycles of 4 days on/1
day off. (a) Survival of IM-9-bearing mice treated with higher doses of
AV-65 was signiﬁcantly prolonged compared with vehicle-treated
mice (P¼0.028). Red, green and blue lines represent the survival rates
of high dose of AV-65 (8mg/kg), low dose of AV-65 (4mg/kg) and
vehicle-treated groups, respectively (10 mice per group). (b) The
complete blood counts of vehicle- of AV-65-treated mice. There was
no signiﬁcant difference between mice treated with the higher doses of
AV-65 and vehicle. Data represent the means±s.d. of four mice in
each group. (c) Inﬂuence on BM hematopoiesis in treated mice. After
four courses of AV-65 treatment, NOD/SCID mice were killed, and
BM cells were obtained. Mononuclear cells were obtained by density
centrifugation and analyzed by colony-forming assay. Colony-forming
assay was performed in duplicate for each mouse (4 mice per group).
There was no signiﬁcant difference between mice treated with the
higher doses of AV-65 and vehicle. Data represent the means±s.e. of
four mice in each group.
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